CHMA - Chiasma presents Mycapssa data from extension study in acromegaly

Chiasma (CHMA) announces long-term safety and efficacy data from the first 48 weeks of open-label extension ((OLE)) of Phase 3 CHIASMA OPTIMAL trial of Mycapssa (octreotide capsules) in in patients with acromegaly. Results show that the average insulin-like growth factor 1 (IGF-1) levels of all Mycapssa-treated patients (n=19) who completed the double-blind placebo-controlled ((DPC)) period were maintained within normal limits at the end of the 48-week OLE period (0.91 at baseline and 0.90 × upper limit of normal at week 48).93% of all patients who enrolled as a responder to Mycapssa  (n=14) maintained their biochemical response at the end of the 48-week OLE period.The safety profile of Mycapssa observed during the OLE was generally consistent with CHIASMA OPTIMAL trial with the number of adverse events decreasing over the time.The results were presented at the Endocrine Society’s annual meeting, being held virtually March 20-23, 2021.Earlier, the company announced positive Mycapssa data from late-stage MPOWERED trial.Shares up

For further details see:

Chiasma presents Mycapssa data from extension study in acromegaly